Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Net Income (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Net Income for 7 consecutive years, with -$94.6 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 34.39% to -$94.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$159.3 million through Dec 2025, up 51.28% year-over-year, with the annual reading at -$159.3 million for FY2025, 51.28% up from the prior year.
  • Net Income hit -$94.6 million in Q4 2025 for IDEAYA Biosciences, down from $108.5 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $108.5 million in Q3 2025 to a low of -$144.1 million in Q4 2024.
  • Historically, Net Income has averaged -$36.7 million across 5 years, with a median of -$29.6 million in 2022.
  • Biggest five-year swings in Net Income: crashed 5179.7% in 2023 and later skyrocketed 262.13% in 2025.
  • Year by year, Net Income stood at -$18.4 million in 2021, then tumbled by 43.95% to -$26.4 million in 2022, then plummeted by 58.52% to -$41.9 million in 2023, then crashed by 243.87% to -$144.1 million in 2024, then surged by 34.39% to -$94.6 million in 2025.
  • Business Quant data shows Net Income for IDYA at -$94.6 million in Q4 2025, $108.5 million in Q3 2025, and -$88.8 million in Q2 2025.